Ethical and legal principles are provided for reviewing the ethics of recent cases of biomedical research abuse involving persons with decisional impairments or legal incapacity who were unable to understand the risks and benefits of the research to which they were subjected. Research abuse continues to occur despite guidance from the Nuremburg Code, the Declaration of Helsinki, the U.S. Belmont Report, extensive federal regulations governing human participant research, and several professional and disciplinary codes of ethics with which, the authors believe, the majority of researchers comply. Contributing to research abuse are weaknesses in the institutional review board and research ethics board review process; conflicting opinions about applicable ethical principles; mounting evidence of pervasive conflicts of interest; and dubious conflated research and marketing practices involving researchers, pharmaceutical and medical device manufacturers, and government research sponsors and regulatory agencies. Several recommendations are made to correct identifiable weaknesses and failures in the governance of biomedical research.
Advisory Committee on Human Radiation Experiments. (1995). Final report (No. 061-000-00-848-9). Washington, DC: U.S. Government Printing Office. Retrieved June 30, 2005, from http://www.eh.doe.gov/ohre/roadmap/achre/index.html
2.
Alliance for Human Research Protection. (2003 , June 26). Testimonies re: Fatal ARDS lung experiment. Retrieved June 30, 2005, from http://www.ahrp.org/infomail/0603/26.php
3.
Alliance for Human Research Protection. (2004 a, March 10). Letter of complaint to Dr. Michael Carome, Chief Compliance Officer, Office of Human Research Protection, U.S. Department of Health and Human Services. Retrieved June 30, 2005, from http://www.ahrp.org/ahrpspeaks/HIVkids0304.php (see also http://www.ahrp.org/infomail/05/04/23a.php )
4.
Alliance for Human Research Protection. (2004 b, December 10). Senator Grassley to offer mandatory drug data registry bill, December 10, 2004. Retrieved June 30, 2005, from http://www.ahrp.org/infomail/04/12/10.php
5.
ARDS Network. (2000). Ventilation with lower tidal volumes compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. New England Journal of Medicine, 342, 1301—1308.
6.
ARDS Network Clinical Coordinating Center. ( 1999, May 20). Report to the Data Safety Monitoring Board on a Phase II/III, randomized, double-blind, placebo-controlled trial of Lisofylline in patients with acute lung injury and adult respiratory distress syndrome . Boston: Massachusetts General Hospital.
7.
Ashcroft, R.E. (2005). Making sense of dignity. Journal of Medical Ethics, 31, 679—682.
8.
Ashcroft, R.E., Newson, A.J., & Benn, P.M.W. (2005). Reforming research ethics committees. British Medical Journal, 331, 587—588.
9.
Avorn, J. (2005). Torcetrapib and atorvastatin: Should marketing drive the research agenda? New England Journal of Medicine , 352, 2573—2576.
10.
Baum, M. (2000). Against strengthening the Declaration of Helsinki . British Medical Journal, 321, 442—445.
11.
Berenson, A. (2005, November 14). Big drug makers see sales decline with their image. New York Times. Retrieved April 10, 2006, from http:// www.nytimes.com/2005/11/14/business/14pharma.html?ex=1144814 400&en=a30706b6b57da33b&ei=5070
12.
Bevan, D.R. (2000). Research ethics: An evolving discipline. Canadian Journal of Anesthesia, 47, 5—9.
13.
Breckler, S. (2005, November 5). The problem with IRBs. APA Online Psychological Science Agenda. Retrieved November 22, 2005, from http://www.apa.org/science/psa/nov05_edprnt.html
14.
Burt, R.A. (1984). Constitutional law and the teaching of the parables . Yale Law Journal, 93, 455—502.
15.
Campbell, D., & Stanley, J. (1963). Experimental and quasi-experimental designs for research. Chicago: Rand McNally .
16.
Chalmers, I. (2006). From optimism to disillusion about commitment to transparency in the medico-industrial complex. Journal of the Royal Society of Medicine, 99, 337—341.
17.
Chalmers, I., & Mathews, R. (2006). What are the implications of optimism bias in clinical research? Lancet, 367, 449—450.
18.
Cochrane Collaboration. (2005, June 29). Cochrane Collaboration: The reliable source of evidence in health care. Retrieved June 30, 2005, from http://www.cochrane.org/index0.htm
19.
Cooper, H. (1989). The integrative research review: A systematic approach. Newbury Park, CA: Sage .
20.
Curfman, G.D., Morrissey, S., & Drazen, J.M. (2005). Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” New Engl J Med2000;343:1520—8. New England Journal of Medicine, 353, 2813—2814.
21.
Deans, K.J., Minneci, P.C., Cui, X., Banks, S.M., Natanson, C., & Eichacker, P.Q. (2005). Editorial—Mechanical ventilation in ARDS: One size does not fit all. Critical Care Medicine, 33, 1141—1143. Retrieved June 30, 2005, from http://www.ahrp.org/infomail/05/05/20.php
22.
Declaration on the Right and Responsibility of Individuals, Groups and Organs of Society to Promote and Protect Universally Recognized Human Rights and Fundamental Freedoms, adopted and proclaimed by United Nations General Assembly resolution 53/144 of March 8, 1999. Retrieved December 7, 2005 , from http://www.unhchr.ch/huridocda/huridoca.nsf/(Symbol)/A.RES.53.144.En?OpenDocument
23.
Dinerstein, R. D., Herr, S. S., & O'Sullivan, J. L. (Eds.) (1999). A guide to consent. Washington, DC: American Association on Mental Retardation .
24.
Drug industry human testing masks death, injury, compliant FDA. (2005, November 2). Bloomberg News, Special Report, News & Commentary. Retrieved December 5, 2004, from http://www.bloomberg.com/apps/news?pid=specialreport&sid=aspHJ_sFen1s&refer
25.
Edwards, S.J.L. (2006). Restricted treatments, inducements, and research participation. Bioethics, 20(2), 77—91.
26.
Eichacker, P.Q., Gerstenberger, E.P., Banks, S.M., Cui, X., & Natanson, C. (2002). Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. American Journal of Respiratory and Critical Care Medicine, 166, 1510—1514. Retrieved June 30, 2005, from http://ajrccm.atsjournals .org/cgi/search?fulltext=eichacker&volume=166&issue=11& journalcode=ajrccm
27.
Eilperin J. (2005, June 28). EPA proposal would allow human tests of pesticides: Draft rule omits some recommended safeguards. Washington Post, p. A13.
28.
Elliott, C. (2005, Fall). When ethicists have conflicts of interest . Dissent, pp. 44—46.
29.
Environmental Protection Agency. (2005, September 12). Protections for subjects in human research: Proposed rule. Federal Register, 70(175), 53837—53866. Retrieved December 8, 2005, from http://www.epa.gov/fedrgstr/EPA-GENERAL/2005/September/Day-12/g18010.htm
30.
Flanagin, A., Carey, L.A., Fontanarosa, P.B., Philips, S.G., Pace, B.P., Lundberg, G.D., et al. (1998). Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. Journal of the American Medical Association, 280, 222—224.
31.
Glannon, W. (2006). Phase I oncology trials: Why the therapeutic misconception will not go away. Journal of Medical Ethics, 32, 252—255.
32.
Godlee, F. (2006). Can we tame the monster?British Medical Journal, 333, 12.
33.
Grimes v. Kennedy-Krieger Institute, Inc. ( 2001). No. 128 September Term, 2000 (Md. 08/16/2001). Retrieved June 30, 2005, from http://biotech.law.lsu.edu/cases/research/grimes_v_KKI.htm
34.
Hammerschmidt, D.E., & Franklin, M. (2005, March). Commentary: Secrecy in medical journals . Minnesota Medicine, pp. 34—35.
35.
Heller, T., Pederson, E.L., & Miller, A.B. (1996). Guidelines from the consumer: Improving consumer involvement in research and training for persons with mental retardation. Mental Retardation, 34, 141—148.
36.
Horng, S., & Grady, C. (2003). Misunderstanding clinical research: Distinguishing therapeutic misconception, therapeutic misestimation and therapeutic optimism . IRB: Ethics and Human Research, 25, 11—16.
37.
House of Commons Health Committee. (2005). The influence of the pharmaceutical industry: Fourth report of session 2004-2005 (Vol. 1). London : U.K. Parliament. Retrieved June 30, 2005, from http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf
38.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1997 ). Good clinical practice: Consolidated guideline (No. CPMP/ICH/153/95) . Retrieved December 5, 2005, from http://emea.eu.int/index/indexh1.htm (Topic E6, Step 5). (Also published by the Food and Drug Administration in the Federal Register [62 FR 25691]).
39.
International Covenant on Civil and Political Rights. (1966 , December 16). Retrieved April 9, 2006, from http://www.unhchr.ch/html/menu3/b/a_ccpr.htm
40.
Jayson, G., & Harris, J. (2006). How participants in cancer trials are chosen: Ethics and conflicting interests. Nature Reviews, 6, 330—336.
41.
Jones, J.H. (1993). Bad blood: The Tuskegee syphilis experiment. New York: Free Press. Tuskegee study historical timeline retrieved June 30, 2005, from http://www.cdc.gov/nchstp/od/tuskegee/time.htm
42.
Karlawish, J.H.T. (2003). Research involving cognitively impaired adults . New England Journal of Medicine, 348, 1389—1392.
43.
Kaufman, M. (2005, May 4). Clinical trials of drugs fewer, study says: Report also notes decline in number of principal investigators in U.SWashington Post, p. A2. Retrieved June 30, 2005, from http://www.ahrp.org/infomail/05/05/04a.php
44.
Koch, T. (2006). Bioethics as ideology: Conditional and unconditional values. Journal of Medicine and Philosophy, 31, 251—267.
45.
Kodish, E.D., Pentz, R.D., Noll, R.B., Ruccione, K., Buckley, J., & Lange, B.J. (1998). Informed consent in the Children's Cancer Group: Results of preliminary research. Cancer, 82, 2467—2481.
46.
Koski, G. (2000, September 12). Testimony of Greg Koski, incoming director, Office of Human Research Protection, U.S. Department of Health and Human Services, before the National Bioethics Advisory Commission . Retrieved April 11, 2006, from http://www.georgetown.edu/research/nrcbl/nbac/transcripts/sept00/9-00day1.pdf
47.
Lawsuit Abuse Reduction Act of 2005 (H.R. 420). Retrieved April 10, 2006, from http://thomas.loc.gov/cgi-bin/cpquery/R?cp109:FLD010:@1(hr123)
48.
Lemmens, T. (2004, Winter). Leopards in the temple: Restoring scientific integrity to the commercialized research scene. International Journal of Comparative Health Law andEthics, pp. 641—657.
49.
Lenzer, J., & Pyke, N. (2005, July 19). Was Traci Johnson driven to suicide by anti-depressants? That's a trade secret, say U.S. officials. On-line Independent (U.K.). Retrieved June 30, 2005, from http://www.ahrp.org/infomail/05/06/19.php
50.
Levine, R.J. (1999). The need to revise the Declaration of Helsinki . New England Journal of Medicine, 341, 531—534.
51.
Lexchin, J., Bero, L.A., Djulbegovic, B., & Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: Systemic review. British Medical Journal , 326, 1167—1170.
52.
Lilford, R.J., & Djulbegovic, B. (2001, February 3) Letters: Declaration of Helsinki should be strengthened. British Medical Journal , 322, 299.
53.
Lying, cheating and stealing in clinical research [Editorial]. ( 2004). Clinical Trials, 1, 475—476.
54.
Marco, C.A. (2005). Impact of detailed informed consent on research subject participation: A prospective, randomized trial. Academic Emergency Medicine, 12(5, Suppl. 80). Retrieved April 10, 2006, from http://www.aemj.org/cgi/content/abstract/12/5_suppl_1/80-a
55.
Martinson, B.C., Anderson, M.S., & deVries, R. (2005, June 9). Scientists behaving badly. Nature, 435, 737—738. Retrieved June 30, 2005, from http://www.nature.com/nature/journal/v435/n7043/full/435737a.html
56.
Mavis, B.E., & Henry, R.C. (2005). Being uninformed on informed consent: A pilot survey of medical education faculty. BMC Medical Education , 5, 12. Retrieved April 10, 2006, from http://www.biomedcentral.com/1472-6920/5/12
57.
McCabe, A.R. (2003). A precarious balancing act: The role of the FDA as protector of public health and industry wealth. Suffolk University Law Review, 36, 787—819.
58.
Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beerman, B. (2003). Evidence b(i)ased medicine—Selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. British Medical Journal, 326, 1171—1173.
59.
Miller, F.G., & Brody, H. (2003). A critique of clinical equipoise: Therapeutic misconception in the ethics of clinical trials. Hastings Center Report, 33(3), 19—28.
60.
Miller, F.G., & Rosenstein, D.L. (2003). The therapeutic orientation to clinical trials. New England Journal of Medicine, 348, 1383-1386
61.
Miller, P.B., & Weijer, C. (2006). Fiduciary obligation in clinical research. Journal of Law, Medicine and Ethics, 34, 424—440.
62.
Morreim, E.H. (2005). The clinical investigator as fiduciary: Discarding a misguided idea. Journal of Law, Medicine and Ethics, 33, 586—598.
63.
Mulkern, A.C. (2004, May 24). When advocates become regulators: President Bush has installed more than 100 top officials who were once lobbyists, attorneys or spokespeople for the industries they oversee. Denver Post . Retrieved June 30, 2005, from http://www.ahrp.org/infomail/04/05/24.php
64.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1979, April 18). The Belmont report: Ethical principles and guidelines for the protection of human subjects of research (No. [OS] 78-0014). Washington, DC: U.S. Government Printing Office. Retrieved June 30, 2005, from http://ohsr.od.nih.gov/guidelines/belmont.html
65.
National Institute of Environmental Health Sciences. (2005). Lead and your health. Retrieved June 30, 2005, from http://www.niehs.nih.gov/oc/factsheets/pdf/lead.pdf
66.
Noble, J.H. (1974). Peer review: Quality control of applied social research. Science, 185, 916—921.
67.
Noble, J.H. (1987). Ethical considerations facing society in rehabilitating severely disabled persons. Marriage and Family Review, 11(1/2), 65—82.
68.
Noble, J.H. (2006). Meta-analysis: Methodology, strengths, weaknesses and political uses. Journal of Laboratory and Clinical Medicine , 147, 7—20.
69.
Nundy, S., & Gulhati, C.M. (2005). A new colonialism? Conducting clinical trials in India. New England Journal of Medicine, 352, 16.
70.
Nuremberg Code. (1949). In A. Mitscherlich & F. Mielke, Doctors of infamy: The story of the Nazi medical crimes (pp. xxiii—xxv). New York: Schuman , 1949. (Original work published 1947) Retrieved June 30, 2005, from http://www.cirp.org/library/ethics/nuremberg/
71.
Office of Human Research Protections. (2005 , May 23). Letter to Columbia University Medical Center and New York Presbyterian Hospital re: Human research protections under multiple project assurance (MPA) M-1356 and federalwide assurances FWA-2635 and FWA-2636 . Retrieved April 10, 2006, from http://www.hhs.gov/ohrp/detrm_letrs/YR05/may05c.pdf
72.
Orlowski, J.P., & Christensen, J.A. (2002). The potentially coercive nature of some clinical trials acronyms. Chest, 121, 2023—2028.
73.
Parexel misled subjects sickened in London study, ethicists say. ( 2006, April 10). Bloomberg News. Retrieved April 10, 2006, from http://www.bloomberg.com/apps/news?pid=10000100&sid=aG3sg1rIkL4U&refer=germany
74.
Pincock, S. (2005, May 19). Wellcome insists on open access. The Scientist. Retrieved June 30, 2005, from http://www.the-scientist.com/news/20050519/01
75.
Principles for the protection of persons with mental illness and the improvement of mental health care, adopted and proclaimed by United Nations General Assembly Resolution 46/119 of December 17, 1991. (1991). Retrieved December 7, 2005, from http://www.unhchr.ch/html/menu3/b/68.htm
76.
Prominent medical school professors and journal editors call for an end to direct to consumer drug ads. (2005, October 29). Newsinferno. Retrieved December 5, 2005, from http://www.newsinferno.com/storypages/10-29-2005%7E001.html
77.
Quitam.com. (2005, June 28). Who can file a qui tam action? Retrieved June 30, 2005, from http://www.quitam.com/quitam4.html
78.
Ramsay, M. (2005). Ethical dilemmas in health care rationing. Newcastleupon-Tyne, UK: Political Studies Association . Retrieved June 30, 2005, from http://www.psa.ac.uk/cps/1995%5Crams.pdf
79.
Rawls, J. (1971). A theory of justice. Cambridge, MA: Belknap.
80.
Richards, T. (2005). Conduct of drug trials in poor countries must improve. British Medical Journal, 330, 1466. Retrieved June 30, 2005, from http://bmj.bmjjournals.com/cgi/content/full/330/7506/1466-a
81.
Roig-Franzia, M. (2001, August). My kids were used as guinea pigs. Washington Post. Retrieved June 30, 2005, from http://www.sskrplaw.com/publications/pigs.html
82.
Rothman, K.J., & Michels, K.B. (2000). For strengthening the Declaration of Helsinki . British Medical Journal, 321, 442—445.
83.
Schatz, G.S. (2003). Are the rationale and regulatory system for protecting human subjects of biomedical and behavioral research obsolete and unworkable, or ethically important but inconvenient and inadequately enforced?Journal of Contemporary Health Law and Policy, 20, 1—31.
84.
Schulman, K.A., Seils, D.M., Timbie, J.W., Sugarman, J., Dame, L.A., Weinfurt, K.P., et al. (2002). A national survey of provisions in clinical trial agreements between medical schools and sponsors. New England Journal of Medicine, 347, 1335—1341.
85.
Sharav, V.H. (2000a, February 2). Chemically induced psychosis experiments: An inhumane paradigm in psychiatric research. Testimony for the record of the Public Health and Safety Subcommittee of the U.S. Senate Health, Education, Labor & Pensions Committee Hearing. Retrieved June 30, 2005, from http://www.ahrp.org/testimonypresentations/InducedPsychosis.php
86.
Sharav, V.H.(2000b, January). Federally-funded relapse producing experiments in psychiatry: Drug washout/chemical provocation—A partial bibliography . Retrieved June 30, 2005, http://www.ahrp.org/testimonypresentations/InducedPsychosisBiblio.php
87.
Sigelman, C.K., Budd, E.C., Spanhel, C.L., & Schoenrock, C.J. (1981). When in doubt, say yes: Acquiescence in interviews and mentally retarded persons. Mental Retardation, 19, 53—58.
88.
Smith, R. (2006). Conflicts of interest: How money clouds objectivity . Journal of the Royal Society of Medicine, 99, 292—297.
89.
Solomon, J. (2005, May 4). Researchers tested AIDS drugs on children . Associated Press. Retrieved June 30, 2005, from http://www.ahrp.org/infomail/05/05/04.php
90.
Tamminga, C.A., Holcomb H.H., Gao, X.-M., & Lahti, A.C. (1995). Glutamate pharmacology and the treatment of schizophrenia: Current status and future directions. International ClinicalPsychopharmacology, 10(Suppl. 3), 29—37.
91.
Taylor, R., & Giles, J. (2005, October 20). Cash interests taint drug advice. Nature, 437, 1070.
92.
Tomossy, G.F. (2006). Vulnerability in research. In I. Freckelton & K. Peterson (Eds.), Disputes and dilemmas in health law (pp. 539—559). Sydney, Australia: Federation Press.
93.
Tomossy, G.F., & Weisstub, D.N. (1997). The reform of adult guardianship laws: The case of non-therapeutic experimentation. International Journal of Law and Psychiatry, 20(1), 113—139.
94.
Toxicology Excellence for Risk Assessment. ( 2002, August). Comparison of common rule with Declaration of Helsinki and good clinical practice. Retrieved December 5, 2005, from http://www.tera.org/pubs/comparisontable.pdf
95.
UCSD Task Force on Decisional Capacity. (2003 , January 7). Procedures for determination of decisional capacity in persons participating in research protocols. Retrieved June 30, 2006, from http://irb.ucsd.edu/DecisionalCapacityAssessment.pdf
96.
Umbc. (2006, June 12). Researcher's guide—Research with children. Retrieved June 30, 2006 , from http://www.umbc.edu/irb/theentireguide_files/Page563.htm
97.
Universal Declaration of Human Rights, adopted and proclaimed by United Nations General Assembly Resolution 217 A (III) of December 10, 1948. Retrieved December 7, 2005, from http://www.unhchr.ch/udhr/lang/eng.htm
98.
University of Bath. (2005, 12 September). Researchers call for end to pharmaceutical industry's “cynical use” of drug studies [press release]. Retrieved November 18, 2007 , from http://www.bath.ac.uk/news/articles/releases/oles120905.html
99.
Weijer, C. (1997). Duty and healing: The lifework of Benjamin Freedman . Canadian Medical Association Journal, 156, 1553—1555.
100.
Wikipedia. (2006). Trade secret . Retrieved April 11, 2006, from http://en.wikipedia.org/wiki/Trade_secret
101.
Willman, D. (2003, December 7). Stealth merger: Drug companies and government medical research: Some of the National Institutes of Health's top scientists are also collecting paychecks and stock options from biomedical firms. Increasingly, such deals are kept secret. Los Angeles Times. Retrieved June 30, 2005, from http://www.ahrp.org/infomail/03/12/07.php
102.
Wilson, M. (2005). Vulnerable subjects and Canadian research governance . IRB: Ethics and Human Research, 27(6), 9—11.
103.
World Medical Assembly. (1964). Declaration of Helsinki (as amended) . British Medical Journal , 313, 1448—1449. Retrieved June 30, 2005, from http://www.cirp.org/library/ethics/helsinki/
104.
Young, D. (1999). Getting to yes or no: Consent and people with developmental disabilities. Rehabilitation Review, 10(1), 1—4. Retrieved July 6, 2006, from http://www.vrri.org/rhb0199.htm
